Used in research and development for targeting lysyl oxidase-like 2 (LOXL2), a protein involved in tissue fibrosis and tumor progression. It has been investigated in clinical trials for treating fibrotic diseases such as liver fibrosis and certain cancers, including pancreatic and colorectal cancer. By inhibiting LOXL2 activity, it may help reduce extracellular matrix remodeling, collagen cross-linking, and tumor metastasis. Its primary application lies in oncology and fibrosis-focused therapeutic strategies, serving as a tool to understand disease mechanisms and evaluate potential treatment efficacy.